US/UK/Canada

Share

Contacts

  • Genovis AB
    Scheelevägen 2 223 70 LUND
    +46 (0)46 10 12 30
    +46 (0)46 12 80 20
    http://www.genovis.com/
    • Pick a time period -
    Tags ( Active)

    Genovis Launches FabRICATOR® Xtra: Next-Generation Enzyme for Future Antibody Therapeutics

    Genovis AB, a leading provider of innovative enzyme technologies, announce the launch of FabRICATOR® Xtra, the second generation of its widely used FabRICATOR (IdeS) enzyme. This newly developed enzyme is specifically designed to address the evolving needs of biopharmaceutical development by efficiently digesting next-generation antibody-based therapeutics with mutations designed to enhance their therapeutic properties.New generations of antibody-based therapeutics, designed with structural mutations, have posed a challenge to traditional enzyme technologies. These therapeutic antibodies,

    Half-Yearly Report January - June 2024

    A stable quarter despite subdued market conditions April – June 2024 · Net sales totaled SEK 29,470 (29,463) thousand, with a growth rate of 0.03%. Adjusted for currency effects, the decrease is -1%.  · Operating profit before depreciation and amortization (EBITDA) totaled SEK 5,272 (7,687) thousand. · Operating profit (EBIT) totaled SEK 2,517 (5,981) thousand. · Profit for the period totaled SEK 1,790 (15,219) thousand.  · Earnings per share totaled SEK 0.03 (0.23).  · Comprehensive income for the period totaled SEK 2,467 (16,843) thousand.  · Cash flow from

    Genovis Announces Strategic Divestment of Antibody Business to Leinco Technologies Inc.

    Genovis, a leading innovator in enzyme technology, today announced the successful divestment of its antibody business to Leinco Technologies Inc., a globally recognized developer of high-quality antibodies for research and diagnostics. This strategic move aligns with Genovis previously communicated focus on optimizing the core business operation and enhancing profitability.The divestment follows a strategic review by Genovis, which identified the need to concentrate on its core enzyme business—a sector where the company has consistently demonstrated market leadership and profitability. The

    Genovis completes a strategic investment in SEQURNA, a developer of next-generation RNase inhibitors

    This strategic investment unlocks new product offerings for Genovis to both existing and new customers and further paves the way for the expansion into new application areas. Genovis will utilize its distribution network to market and sell SEQURNA’s RNase inhibitors alongside its own catalogue of innovative tools for the biopharmaceutical and research industries.Following the investment, Genovis will own 25 percent of SEQURNA. As part of the transaction, the parties have agreed to a call option with an end date on 30 June 2027, providing Genovis the right to acquire all shares of SEQURNA

    Communiqué from Genovis AB (publ) Annual General Meeting May 15, 2024

    The Annual General Meeting adopted the following resolutions:· The Balance Sheet and Income Statement as well as the Consolidated Income Statement and the Consolidated Balance Sheet were adopted. · The Board and the Chief Executive Officer were discharged from liability. · The Board shall consist until the next AGM of five ordinary members without deputies. · Re-election of Board members Torben Jørgensen, Mikael Lönn, Lotta Ljungqvist, Steve Jordan and Magnus Gustafsson. Torben Jørgensen was elected Chairperson of the Board. · Remuneration will be paid to the Board of

    Interim Report January – March 2024

    Best quarter for enzyme business in analytics and stronger cash position January – March 2024 · Net sales totaled SEK 40,057 (71,276) thousand, with a growth rate of -44%. Adjusted for currency effects, the decrease is -44%. Organic growth adjusted for license revenue is 0.4%, and 0.5% when also adjusted for currency effects.  · Operating profit before depreciation and amortization (EBITDA) totaled SEK 18,568 (45,089) thousand. Adjusted for license revenue and related costs, EBITDA is SEK 8,440 (6,223) thousand. · Operating profit (EBIT) totaled SEK 15,833 (43,399) thousand.

    Genovis Annual Report 2023 published

    Genovis 2023 Annual Report is now available in Swedish and English at our website.To read or download the annual report in Swedish, go to: https://investor.genovis.com/wp-content/uploads/Genovis_AR_2023_Sv.pdf To read or download the annual report in English, go to: https://investor.genovis.com/wp-content/uploads/Genovis_AR_2023_En.pdf For more information, please contact: Fredrik Olsson, CEO, Genovis AB T+46 (0)70 276 46 56 E:  fredrik.olsson@genovis.com

    NOTICE CONVENING THE 2024 ANNUAL GENERAL MEETING

    Genovis AB will hold its Annual General Meeting of Shareholders at 5:00 p.m. on May 15, 2024, at Karl Johans väg 104, Kävlinge. 4:30 p.m. – 4:50 p.m. Registration 5:00 pm Annual General Meeting convenedRight to participate. Registration Shareholders who are registered in the register of shareholders maintained by Euroclear Sweden AB on May 6, 2024, and who have notified the company of their intention to attend the Annual General Meeting by no later than May 8, 2024, preferably before 3:00 p.m., have the right to attend the Annual General Meeting. Notification may be made by mail at

    Carthesian Therapeutics terminates Genovis Licence Agreement

    On 21 October 2021 Genovis entered into a license agreement with Selecta Biocience/Carhtesian Therapeutics. This license agreement has now been terminated by Carthesian Therapeutics and all right to the unique Xork™ enzyme are returned to Genovis. This opens up for new business opportunities with other partners within gene therapy and autoimmune diseases.Substantial resources have already been invested in the project, which now will be for the benefit of Genovis, amongst other items second and third generation of the Xork enzyme with corresponding patent applications. Currently there are no

    Year-end report January-December 2023

    Our best year - focus on continued growth October – December 2023     · Net sales totaled SEK 27,306 (25,741) thousand, with a growth rate of 6%. Growth is 4%, adjusted for currency effects. · Operating profit before depreciation and amortization (EBITDA) totaled SEK 3,615 (-5,915) thousand. Adjusted for non-recurring costs of moving to new premises, EBITDA is SEK 3,721 thousand. · Operating profit (EBIT) totaled SEK 355 (-7,043) thousand. Adjusted for non-recurring costs for moving to new premises, EBIT is SEK 760 thousand. · Profit for the period totaled SEK -422 (-7,508)

    Genovis to receive USD 1 million in milestone compensation related to the development of the Xork™ enzyme

    The milestone compensation is related to achieved development targets for the Xork enzyme that Genovis has out-licensed for therapeutic applications, primarily as a potential pre-treatment in gene therapy but also for autoimmune diseases.Xork is derived from a streptococcal bacterial strain that does not infect humans. The pre-clinical data generated to date highlights Xork’s differentiated profile demonstrating very low cross-reactivity with naturally occurring antibodies in human sera while retaining efficient and specific cleavage of human IgG antibodies.

    Genovis AB changes Certified Adviser to Carnegie Investment Bank AB (publ)

    Genovis AB today announces a change of Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB (publ). The reason for the change is that Carnegie Investment Bank AB has acquired certain operations, including the Certified Adviser operations, from Erik Penser Bank AB.Genovis AB has entered into an agreement with Carnegie Investment Bank AB (publ) regarding the position as Certified Adviser. Carnegie Investment Bank AB (publ) will take over as Certified Adviser on November 30, 2023. Until then, Erik Penser Bank AB will continue to act as Certified Adviser to the company.

    Interim Report January-September 2023

    Strong growth and investments for the future July – September 2023    · Net sales totaled SEK 30,186 (22,979) thousand, with a growth rate of 31%. Growth is 25%, adjusted for currency effects. Organic growth adjusted for license revenues in 2022 is 41%, and 34% when also adjusted for currency effects.    · Operating profit before depreciation and amortization (EBITDA) totaled SEK 7,555 (6,997) thousand. Adjusted for non-recurring costs for moving to new premises, EBITDA is SEK 8,193 thousand. · Operating profit (EBIT) totaled SEK 4,488 (4,993) thousand. Adjusted for non-

    Half-Yearly Report January-June 2023

    Continued strong growth in both enzyme and antibody business  April – June 2023 · Net sales totaled SEK 29,463 (21,093) thousand, with a growth rate of 40%. Growth is 30%, adjusted for currency effects.   · Operating profit before depreciation and amortization (EBITDA) totaled SEK 7,687 (2,109) thousand. · Operating profit (EBIT) totaled SEK 5,981 (221) thousand. · Profit for the period totaled SEK 15,219 (672) thousand. · Earnings per share totaled SEK 0.23 (0.01). · Comprehensive income for the period totaled SEK 16,843 (811) thousand. · Cash flow from operating

    Genovis launch Innovative IgM-Specific Protease with Wide-Ranging Applications in Life Science Markets

    As a leading innovator in the field of enzyme technology, Genovis today announces the launch of its cutting-edge IgM-specific protease. This highly efficient and specific enzyme holds significant potential within various life science sectors, including research, diagnostics and therapeutic applications.The newly developed IgM-specific protease demonstrates a remarkable level of effectiveness, exhibiting exceptional specificity towards IgM antibodies, which play a critical role in the early stages of immune response. These characteristics positions the enzyme as a valuable tool for cutting-

    Communiqué from Genovis AB (publ) Annual General Meeting May 16, 2023

    The Board withdrew its proposal regarding authorizing the Board of Directors to decide on the issuance of shares, item 17 in the notice.The Annual General Meeting adopted the following resolutions: · The Balance Sheet and Income Statement as well as the Consolidated Income Statement and the Consolidated Balance Sheet were adopted. · The Board and the Chief Executive Officer were discharged from liability. · The Board shall consist until the next AGM of five ordinary members without deputies. · Re-election of Board members Torben Jørgensen, Mikael Lönn, Lotta Ljungqvist,

    Interim Report January-March 2023

    Record earnings and strong growth in all areas of the business January-March 2023 · Net sales totaled SEK 71,276 (32,574) thousand, with a growth rate of 119%. Growth is 107%, adjusted for currency effects. Net sales include USD 4 million in license revenues from Selecta Biosciences. Organic growth adjusted for license revenues from Selecta Biosciences is 41%, and 30% when also adjusted for currency effects.  · Gross profit totaled SEK 67,098 (29,419) thousand. · Operating profit before depreciation and amortization (EBITDA) totaled SEK 45,089 (11,717) thousand. · Operating

    Genovis and ArcticZymes Technologies enter into a collaboration agreement to accelerate growth in China

    Genovis and ArcticZymes are excited to announce a collaboration to speed up penetration and growth in the Chinese market. The collaboration will create several synergies that will allow both companies to tap into the projected growth potential in China for their respective market segments. The focus of the collaboration will be on sharing Business Development resources and engaging in joint marketing activities.  The joint effort will allow both companies to have a direct presence in the Chinese market with local resources.According to Dirk Hahneiser, VP of Business Development & Marketing,

    Genovis acquires IP Rights to novel enzymes for applications within genomics

    Today, Genovis has acquired the patent rights to a unique DNA polymerase developed by researchers at Uppsala University. The enzyme has potential applications in research, diagnostics and forensics.As a leading developer of enzymes for the life science industry, Genovis has acquired the rights to a new enzyme developed by researchers at Uppsala University, led by Professor Ola Söderberg. "We have developed a new type of DNA polymerase with properties that could not have arisen naturally. This laboratory-created DNA polymerase opens up fantastic opportunities for biotechnology and medical

    NOTICE CONVENING THE 2023 ANNUAL GENERAL MEETING

    Genovis AB will hold its Annual General Meeting of Shareholders at 5:00 p.m. on Tuesday, May 16, 2023 at Medicon Village Scheeletorget 1, Lund (restaurant Inspira/Auditorium). Participants may register upon arrival at the reception desk by the Auditorium. 4:30 p.m. – 4:50 p.m. Registration     5:00 pm Annual General Meeting convened Right to participate. Registration Shareholders who are registered in the register of shareholders maintained by Euroclear Sweden AB on May 8, 2023 and who have notified the company of their intention to attend the Annual General Meeting by no later

    Year-end Report January-December 2022

    The strong growth in the core business during the fourth quarter continues in the beginning of 2023 October-December 2022 · Net sales totaled SEK 25,741 (42,060) thousand. Organic growth adjusted for license revenue from Selecta Biosciences in 2021 is 38% and when also adjusted for currency effect 21%. Net sales including license revenue from Selecta Biosciences decreased by -39% and adjusted for currency effect -48%. · Gross profit totaled SEK 23,031 (39,024) thousand. · Operating profit before depreciation and amortization (EBITDA) totaled SEK -5,915 (23,361) thousand.

    Genovis to receive 4 MUSD upfront after Selecta Biosciences sublicensed Xork™ enzyme to Astellas Pharma

    Today Selecta Biosciences announced the sublicensing of the Xork enzyme to Astellas Pharma for development with AT845, an investigational Astellas Gene Therapies’ product, for the treatment of Pompe Disease.As part of the licensing agreement entered between Genovis AB and Selecta Biosciences Inc. in 2021, Genovis will receive 4 MUSD upfront following the sublicensing of the Xork enzyme from Selecta Bioscience Inc. to Astellas Pharma Inc. Genovis is eligible to receive additional sublicense revenues up to 135 MUSD from development and commercialization plus royalties on sales where Xork and

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media